Ann Hynes
Stock Analyst at Mizuho
(4.37)
# 372
Out of 5,113 analysts
279
Total ratings
63.46%
Success rate
12.8%
Average return
Main Sectors:
Stocks Rated by Ann Hynes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SGRY Surgery Partners | Maintains: Outperform | $22 → $19 | $14.85 | +27.95% | 4 | Dec 18, 2025 | |
| HCA HCA Healthcare | Maintains: Outperform | $505 → $520 | $491.23 | +5.86% | 23 | Dec 18, 2025 | |
| FTRE Fortrea Holdings | Maintains: Neutral | $11 → $13 | $16.73 | -22.30% | 6 | Dec 18, 2025 | |
| CRL Charles River Laboratories International | Maintains: Neutral | $174 → $200 | $216.88 | -7.78% | 4 | Dec 18, 2025 | |
| BTSG BrightSpring Health Services | Maintains: Outperform | $38 → $42 | $39.55 | +6.19% | 3 | Dec 18, 2025 | |
| ARDT Ardent Health | Maintains: Outperform | $20 → $12 | $8.25 | +45.45% | 4 | Dec 18, 2025 | |
| ACHC Acadia Healthcare Company | Maintains: Neutral | $22 → $17 | $13.44 | +26.49% | 13 | Dec 18, 2025 | |
| CVS CVS Health | Maintains: Outperform | $88 → $95 | $74.03 | +28.33% | 12 | Dec 10, 2025 | |
| ELV Elevance Health | Maintains: Outperform | $420 → $400 | $341.85 | +17.01% | 6 | Nov 4, 2025 | |
| MEDP Medpace Holdings | Maintains: Outperform | $575 → $655 | $597.91 | +9.55% | 5 | Oct 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $194 → $225 | $189.58 | +18.68% | 16 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $190 → $210 | $182.74 | +14.92% | 16 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $285 → $320 | $268.04 | +19.39% | 16 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $300 → $430 | $294.02 | +46.25% | 21 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $300 → $345 | $194.01 | +77.83% | 9 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $28 → $40 | $41.90 | -4.53% | 9 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $190 → $225 | $239.76 | -6.16% | 13 | Jul 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $173 → $225 | $186.32 | +20.76% | 16 | Jul 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $400 → $330 | $187.00 | +76.47% | 9 | Jul 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $15 | $20.67 | -27.43% | 11 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $110 → $120 | $210.39 | -42.96% | 8 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $21.48 | +30.35% | 1 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $93 → $95 | $95.70 | -0.73% | 8 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $370 → $385 | $272.38 | +41.35% | 10 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $175 → $200 | $203.02 | -1.49% | 15 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $242 → $268 | $2.13 | +12,482.16% | 1 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $450 → $505 | $826.62 | -38.91% | 19 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $57 | $0.93 | +6,029.03% | 1 | Sep 21, 2017 |
Surgery Partners
Dec 18, 2025
Maintains: Outperform
Price Target: $22 → $19
Current: $14.85
Upside: +27.95%
HCA Healthcare
Dec 18, 2025
Maintains: Outperform
Price Target: $505 → $520
Current: $491.23
Upside: +5.86%
Fortrea Holdings
Dec 18, 2025
Maintains: Neutral
Price Target: $11 → $13
Current: $16.73
Upside: -22.30%
Charles River Laboratories International
Dec 18, 2025
Maintains: Neutral
Price Target: $174 → $200
Current: $216.88
Upside: -7.78%
BrightSpring Health Services
Dec 18, 2025
Maintains: Outperform
Price Target: $38 → $42
Current: $39.55
Upside: +6.19%
Ardent Health
Dec 18, 2025
Maintains: Outperform
Price Target: $20 → $12
Current: $8.25
Upside: +45.45%
Acadia Healthcare Company
Dec 18, 2025
Maintains: Neutral
Price Target: $22 → $17
Current: $13.44
Upside: +26.49%
CVS Health
Dec 10, 2025
Maintains: Outperform
Price Target: $88 → $95
Current: $74.03
Upside: +28.33%
Elevance Health
Nov 4, 2025
Maintains: Outperform
Price Target: $420 → $400
Current: $341.85
Upside: +17.01%
Medpace Holdings
Oct 24, 2025
Maintains: Outperform
Price Target: $575 → $655
Current: $597.91
Upside: +9.55%
Oct 17, 2025
Maintains: Outperform
Price Target: $194 → $225
Current: $189.58
Upside: +18.68%
Oct 17, 2025
Maintains: Outperform
Price Target: $190 → $210
Current: $182.74
Upside: +14.92%
Oct 17, 2025
Maintains: Outperform
Price Target: $285 → $320
Current: $268.04
Upside: +19.39%
Oct 9, 2025
Maintains: Outperform
Price Target: $300 → $430
Current: $294.02
Upside: +46.25%
Oct 9, 2025
Maintains: Outperform
Price Target: $300 → $345
Current: $194.01
Upside: +77.83%
Oct 9, 2025
Maintains: Neutral
Price Target: $28 → $40
Current: $41.90
Upside: -4.53%
Jul 25, 2025
Maintains: Outperform
Price Target: $190 → $225
Current: $239.76
Upside: -6.16%
Jul 25, 2025
Maintains: Outperform
Price Target: $173 → $225
Current: $186.32
Upside: +20.76%
Jul 11, 2025
Maintains: Outperform
Price Target: $400 → $330
Current: $187.00
Upside: +76.47%
Nov 19, 2024
Maintains: Neutral
Price Target: $13 → $15
Current: $20.67
Upside: -27.43%
Nov 4, 2024
Maintains: Neutral
Price Target: $110 → $120
Current: $210.39
Upside: -42.96%
Aug 19, 2024
Initiates: Outperform
Price Target: $28
Current: $21.48
Upside: +30.35%
Apr 25, 2024
Maintains: Buy
Price Target: $93 → $95
Current: $95.70
Upside: -0.73%
Mar 8, 2024
Maintains: Buy
Price Target: $370 → $385
Current: $272.38
Upside: +41.35%
Mar 6, 2024
Maintains: Buy
Price Target: $175 → $200
Current: $203.02
Upside: -1.49%
Feb 23, 2024
Maintains: Buy
Price Target: $242 → $268
Current: $2.13
Upside: +12,482.16%
Feb 9, 2024
Maintains: Neutral
Price Target: $450 → $505
Current: $826.62
Upside: -38.91%
Sep 21, 2017
Initiates: Neutral
Price Target: $57
Current: $0.93
Upside: +6,029.03%